Inhibition of histone deacetylase 1 (HDAC1) and HDAC2 enhances CRISPR/Cas9 genome editing
Open accessPublished version of a preprint
The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
Despite the rapid development of CRISPR/Cas9-mediated gene editing technology, the gene editing potential of CRISPR/Cas9 is hampered by low efficiency, especially for clinical applications. One of the major challenges is that chromatin compaction inevitably limits the Cas9 protein access to the target DNA. However, chromatin compaction is precisely regulated by histone acetylation and deacetylation. To overcome these challenges, we have comprehensively assessed the impacts of histone modifiers such as HDAC (1–9) inhibitors and HAT (p300/CBP, Tip60 and MOZ) inhibitors, on CRISPR/Cas9 mediated gene editing efficiency. Our findings demonstrate that attenuation of HDAC1, HDAC2 activity, but not other HDACs, enhances CRISPR/Cas9-mediated gene knockout frequencies by NHEJ as well as gene knock-in by HDR. Conversely, inhibition of HDAC3 decreases gene editing frequencies. Furthermore, our study showed that attenuation of HDAC1, HDAC2 activity leads to an open chromatin state, facilitates Cas9 access and binding to the targeted DNA and increases the gene editing frequencies. This approach can be applied to other nucleases, such as ZFN and TALEN.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
Crystal structure of the nucleosome core particle at 2.8 Å resolution
Luger, K., Mäder, A. W., Richmond, R. K., Sargent, D. F., & Richmond, T. J. (1997) · Nature · doi:10.1038/38444 · Cited by 9,466
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity
Ran, F. A., Hsu, P. D., Lin, C.-Y., Gootenberg, J. S., Konermann, S., Trevino, A. E., Scott, D. A., Inoue, A., Matoba, S., Zhang, Y., et al. (2013) · Cell · doi:10.1016/j.cell.2013.08.021 · Cited by 3,299
Histone acetylation in chromatin structure and transcription
Grunstein, M. (1997) · Nature · doi:10.1038/38664 · Cited by 2,884
CRISPR/Cas, the Immune System of Bacteria and Archaea
Horvath, P., & Barrangou, R. (2010) · Science · doi:10.1126/science.1179555 · Cited by 2,465
Bae, S., Park, J., & Kim, J.-S. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu048 · Cited by 2,339
C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector
Abudayyeh, O. O., Gootenberg, J. S., Konermann, S., Joung, J., Slaymaker, I. M., Cox, D. B. T., Shmakov, S., Makarova, K. S., Semenova, E., Minakhin, L., et al. (2016) · Science · doi:10.1126/science.aaf5573 · Cited by 2,336
RNA targeting with CRISPR–Cas13
Abudayyeh, O. O., Gootenberg, J. S., Essletzbichler, P., Han, S., Joung, J., Belanto, J. J., Verdine, V., Cox, D. B. T., Kellner, M. J., Regev, A., et al. (2017) · Nature · doi:10.1038/nature24049 · Cited by 2,093
Improving CRISPR-Cas nuclease specificity using truncated guide RNAs
Fu, Y., Sander, J. D., Reyon, D., Cascio, V. M., & Joung, J. K. (2014) · Nature Biotechnology · doi:10.1038/nbt.2808 · Cited by 1,993 · cited 1×
“To overcome these challenges, we have comprehensively assessed the impacts of histone modifiers such as HDAC (1-9) inhibitors and HAT (p300/CBP, Tip60 and MOZ) inhibitors, on CRISPR/Cas9 mediated gene editing efficiency.”
BackgroundHilton, I. B., D'Ippolito, A. M., Vockley, C. M., Thakore, P. I., Crawford, G. E., Reddy, T. E., & Gersbach, C. A. (2015) · Nature Biotechnology · doi:10.1038/nbt.3199 · Cited by 1,885
RNA-guided gene activation by CRISPR-Cas9-based transcription factors
Perez-Pinera, P., Kocak, D. D., Vockley, C. M., Adler, A. F., Kabadi, A. M., Polstein, L. R., Thakore, P. I., Glass, K. A., Ousterout, D. G., Leong, K. W., et al. (2013) · Nature Methods · doi:10.1038/nmeth.2600 · Cited by 1,328
CRISPR–Cas9 genome editing induces a p53-mediated DNA damage response
Haapaniemi, E., Botla, S., Persson, J., Schmierer, B., & Taipale, J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0049-z · Cited by 1,264
Richardson, C. D., Ray, G. J., DeWitt, M. A., Curie, G. L., & Corn, J. E. (2016) · Nature Biotechnology · doi:10.1038/nbt.3481 · Cited by 1,098
p53 inhibits CRISPR–Cas9 engineering in human pluripotent stem cells
Ihry, R. J., Worringer, K. A., Salick, M. R., Frias, E., Ho, D., Theriault, K., Kommineni, S., Chen, J., Sondey, M., Ye, C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0050-6 · Cited by 978
Eberharter, A., & Becker, P. B. (2002) · EMBO reports · doi:10.1093/embo-reports/kvf053 · Cited by 948
CRISPR-Cas Systems in Bacteria and Archaea: Versatile Small RNAs for Adaptive Defense and Regulation
Bhaya, D., Davison, M., & Barrangou, R. (2011) · Annual Review of Genetics · doi:10.1146/annurev-genet-110410-132430 · Cited by 914
Comparison of nonhomologous end joining and homologous recombination in human cells
MAO, Z., BOZZELLA, M., SELUANOV, A., & GORBUNOVA, V (2008) · DNA Repair · doi:10.1016/j.dnarep.2008.06.018 · Cited by 671
CRISPR/Cas System and Its Role in Phage-Bacteria Interactions
Deveau, H., Garneau, J. E., & Moineau, S. (2010) · Annual Review of Microbiology · doi:10.1146/annurev.micro.112408.134123 · Cited by 623
Histone acetyl transferases as emerging drug targets
Dekker, F. J., & Haisma, H. J. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.06.008 · Cited by 315
Self-citationCAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors
Alemany, R., & Curiel, D. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301515 · Cited by 294
Improving CRISPR-Cas specificity with chemical modifications in single-guide RNAs
Ryan, D. E., Taussig, D., Steinfeld, I., Phadnis, S. M., Lunstad, B. D., Singh, M., Vuong, X., Okochi, K. D., McCaffrey, R., Olesiak, M., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1199 · Cited by 280
Pinder, J., Salsman, J., & Dellaire, G. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv993 · Cited by 279
A compact, high-accuracy Cas9 with a dinucleotide PAM for in vivo genome editing
Edraki, A., Mir, A., Ibraheim, R., Gainetdinov, I., Yoon, Y., Song, C.-Q., Cao, Y., Gallant, J., Xue, W., Rivera-Pérez, J. A., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2018.12.003 · Cited by 265
Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat
Tate, C. R., Rhodes, L. V., Segar, H. C., Driver, J. L., Pounder, F. N., Burow, M. E., & Collins-Burow, B. M. (2012) · Breast Cancer Research · doi:10.1186/bcr3192 · Cited by 260
Histone degradation in response to DNA damage enhances chromatin dynamics and recombination rates
Hauer, M. H., Seeber, A., Singh, V., Thierry, R., Sack, R., Amitai, A., Kryzhanovska, M., Eglinger, J., Holcman, D., Owen-Hughes, T., et al. (2017) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3347 · Cited by 255
Functional Domains of Histone Deacetylase-3
Yang, W.-M., Tsai, S.-C., Wen, Y.-D., Fejér, G., & Seto, E. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m105993200 · Cited by 248
Locus-specific histone deacetylation using a synthetic CRISPR-Cas9-based HDAC
Kwon, D. Y., Zhao, Y.-T., Lamonica, J. M., & Zhou, Z. (2017) · Nature Communications · doi:10.1038/ncomms15315 · Cited by 246
MNase titration reveals differences between nucleosome occupancy and chromatin accessibility
Mieczkowski, J., Cook, A., Bowman, S. K., Mueller, B., Alver, B. H., Kundu, S., Deaton, A. M., Urban, J. A., Larschan, E., Park, P. J., et al. (2016) · Nature Communications · doi:10.1038/ncomms11485 · Cited by 245
Nucleosome breathing and remodeling constrain CRISPR-Cas9 function
Isaac, R. S., Jiang, F., Doudna, J. A., Lim, W. A., Narlikar, G. J., & Almeida, R. (2016) · eLife · doi:10.7554/elife.13450 · Cited by 234 · cited 3×
“For instance, a study shows that nucleosomes inhibit CRISPRCas9 cleavage activity via blocking binding of Cas9 to PAM sites (20).”
BackgroundNucleosomes inhibit target cleavage by CRISPR-Cas9 in vivo
Yarrington, R. M., Verma, S., Schwartz, S., Trautman, J. K., & Carroll, D. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1810062115 · Cited by 194
A High-Throughput Platform to Identify Small-Molecule Inhibitors of CRISPR-Cas9
Maji, B., Gangopadhyay, S. A., Lee, M., Shi, M., Wu, P., Heler, R., Mok, B., Lim, D., Siriwardena, S. U., Paul, B., et al. (2019) · Cell · doi:10.1016/j.cell.2019.04.009 · Cited by 188
Bornelöv, S., Reynolds, N., Xenophontos, M., Gharbi, S., Johnstone, E., Floyd, R., Ralser, M., Signolet, J., Loos, R., Dietmann, S., et al. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.06.003 · Cited by 184
The influence of eukaryotic chromatin state on CRISPR–Cas9 editing efficiencies
Verkuijl, S. A. N., & Rots, M. G. (2018) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2018.07.005 · Cited by 168
Probing the impact of chromatin conformation on genome editing tools
Chen, X., Rinsma, M., Janssen, J. M., Liu, J., Maggio, I., & Gonçalves, M. A. F. V. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw524 · Cited by 155
Maggio, I., Holkers, M., Liu, J., Janssen, J. M., Chen, X., & Gonçalves, M. A. F. V. (2014) · Scientific Reports · doi:10.1038/srep05105 · Cited by 149
Adenoviral vector DNA for accurate genome editing with engineered nucleases
Holkers, M., Maggio, I., Henriques, S. F. D., Janssen, J. M., Cathomen, T., & Gonçalves, M. A. F. V. (2014) · Nature Methods · doi:10.1038/nmeth.3075 · Cited by 138
Histone deacetylase 3 localizes to the plasma membrane and is a substrate of Src
Longworth, M. S., & Laimins, L. A. (2006) · Oncogene · doi:10.1038/sj.onc.1209473 · Cited by 126
NmeCas9 is an intrinsically high-fidelity genome-editing platform
Amrani, N., Gao, X. D., Liu, P., Edraki, A., Mir, A., Ibraheim, R., Gupta, A., Sasaki, K. E., Wu, T., Donohoue, P. D., et al. (2018) · Genome Biology · doi:10.1186/s13059-018-1591-1 · Cited by 125
Chromatin accessibility is associated with CRISPR-Cas9 efficiency in the zebrafish (Danio rerio)
Uusi-Mäkelä, M. I. E., Barker, H. R., Bäuerlein, C. A., Häkkinen, T., Nykter, M., & Rämet, M. (2018) · PLoS ONE · doi:10.1371/journal.pone.0196238 · Cited by 123
Inhibition of Histone Deacetylase 3 Causes Replication Stress in Cutaneous T Cell Lymphoma
Wells, C. E., Bhaskara, S., Stengel, K. R., Zhao, Y., Sirbu, B. M., Chagot, B., Cortez, D., Khabele, D., Chazin, W., Cooper, A. C., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068915 · Cited by 108
CRISPR/Cas9: a powerful tool for identification of new targets for cancer treatment
Liu, B., Saber, A., & Haisma, H. J. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.02.011 · Cited by 90
Self-citationJanssen, J. M., Chen, X., Liu, J., & Gonçalves, M. A. F. V. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.02.009 · Cited by 57
The Chromatin Structure Differentially Impacts High-Specificity CRISPR-Cas9 Nuclease Strategies
Chen, X., Liu, J., Janssen, J. M., & Gonçalves, M. A. F. V. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.08.005 · Cited by 47
Analysis of Nucleosome Positioning Using a Nucleosome-Scanning Assay
Infante, J. J., Law, G. L., & Young, E. T. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-477-3_5 · Cited by 41
Janssen, J. M., Liu, J., Skokan, J., Gonçalves, M. A. F. V., & de Vries, A. A. F. (2012) · The Journal of Gene Medicine · doi:10.1002/jgm.2687 · Cited by 30
Stable transduction of large DNA by high-capacity adeno-associated virus/adenovirus hybrid vectors
Gonçalves, M. A. F. V., van der Velde, I., Knaän‐Shanzer, S., Valerio, D., & de Vries, A. A. F. (2004) · Virology · doi:10.1016/j.virol.2004.01.007 · Cited by 26
Cao, F., Zwinderman, M. R. H., van Merkerk, R., Ettema, P. E., Quax, W. J., & Dekker, F. J. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.05.038 · Cited by 24
Self-citationJoglekar, A. V., Stein, L., Ho, M., Hoban, M. D., Hollis, R. P., & Kohn, D. B. (2014) · Human Gene Therapy · doi:10.1089/hum.2013.211 · Cited by 22
Cell Counting and Viability Measurements
Butler, M. J. (2003) · Humana Press eBooks · doi:10.1385/0-89603-547-6:131 · Cited by 9
Research works printed but not linked: 3
- Hemelaar, 2017, Nanodiamonds as multi-purpose labels for microscopy, Sci. Rep., 7, 720, 10.1038/s41598-017-00797-2 · doi:10.1038/s41598-017-00797-2
- Janssen, 2019, The chromatin structure of CRISPR-Cas9 target DNA controls the balance between mutagenic and homology-directed gene-editing events, Mol. Ther. Nucleic Acids, 16, 141, 10.1016/j.omtn.2019.02.009 · DOI
- PLOS Biology Staff, 2019, Correction: Heterochromatin delays CRISPR-Cas9 mutagenesis but does not influence the outcome of mutagenic DNA repair, PLoS Biol., 17, e3000160, 10.1371/journal.pbio.3000160 · doi:10.1371/journal.pbio.3000160
Cited by
Profiling the human intestinal environment under physiological conditions
Shalon, D., Culver, R. N., Grembi, J. A., Folz, J., Treit, P. V., Shi, H., Rosenberger, F. A., Dethlefsen, L., Meng, X., Yaffe, E., et al. (2023) · Nature · doi:10.1038/s41586-023-05989-7 · Cited by 484
Artificial intelligence for natural product drug discovery
Mullowney, M. W., Duncan, K. R., Elsayed, S. S., Garg, N., van der Hooft, J. J. J., Martin, N. I., Meijer, D., Terlouw, B. R., Biermann, F., Blin, K., et al. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00774-7 · Cited by 460
Antibiotic perturbations to the gut microbiome
Fishbein, S. R. S., Mahmud, B., & Dantas, G. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-023-00933-y · Cited by 440
Co-selection for antibiotic resistance by environmental contaminants
Murray, L. M., Hayes, A., Snape, J., Kasprzyk-Hordern, B., Gaze, W. H., & Murray, A. K. (2024) · npj Antimicrobials and Resistance · doi:10.1038/s44259-024-00026-7 · Cited by 310
High-throughput microbial culturomics using automation and machine learning
Huang, Y., Sheth, R. U., Zhao, S., Cohen, L. A., Dabaghi, K., Moody, T., Sun, Y., Ricaurte, D., Richardson, M., Velez-Cortes, F., et al. (2023) · Nature Biotechnology · doi:10.1038/s41587-023-01674-2 · Cited by 283
Metadata
- Authors
- Liu, B., Chen, S., Rose, A. L., Chen, D., Cao, F., Zwinderman, M., Kiemel, D., Aïssi, M., Dekker, F. J., & Haisma, H. J.
- Venue
- Nucleic Acids Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-12-04
- Volume
- 48
- Issue
- 2
- Pages
- 517-532
- ISSN
- 0305-1048 (ISSN-L)
- 1362-4962
- OpenAlex
- W2993752344
- Cited by
- 370
- References
- 51
- FWCI
- 11.46
- Type
- journal article
- Language
- en
- Open access
- gold
- Funders
- University of Groningen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.